PP
PGNX

PDT Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

PDT Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-35,800
Closed -$182K – 924
2019
Q4 		$182K Sell
35,800
-481
-1% -$2.54K 0.01% 656
2019
Q3 		$183K Sell
36,281
-103,619
-74% -$517K 0.01% 416
2019
Q2 		$863K Sell
139,900
-12,300
-8% -$59.3K 0.05% 264
2019
Q1 		$706K Buy
+152,200
New +$689K 0.04% 285
2015
Q3 		– Sell
-26,606
Closed -$198K – 1697
2015
Q2 		$198K Buy
+26,606
New +$161K 0.01% 1242

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PDT Partners's PGNX Position: Q1 2020 in Review

PDT Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 35,800 shares — an estimated $182K sold.

PDT Partners first reported a position in PGNX in Q2 2015 and held it in 5 quarters. The position peaked at $863K in Q2 2019. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

  • PDT Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
  • PDT Partners sold 35,800 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $182K.
  • PDT Partners first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 5 quarters.
  • PDT Partners's Progenics Pharmaceuticals Inc position peaked at $863K in Q2 2019.
  • 129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on PDT Partners's 13F filing for Q1 2020, filed 15 May 2020.